文献速递肝病

部分MCT1失活可预防饮食诱导的非酒精性脂肪性肝病及相关脑功能障碍

Partial MCT1 invalidation protects against diet-induced non-alcoholic fatty liver disease and the associated brain dysfunction.
PubMed 文献 · J Hepatol · 2022-08-19

本研究利用高脂饮食及高果糖/葡萄糖饮水诱导的非酒精性脂肪性肝病(NAFLD)小鼠模型和Mct1单倍体不足小鼠,发现NAFLD伴肥胖与焦虑抑郁样行为、脑组织低氧、脑血容量降低及胶质细胞形态代谢改变相关,而Mct1单倍体不足小鼠虽脂肪组织堆积却免于NAFLD及相关脑改变。

要点

  • NAFLD伴肥胖小鼠出现焦虑抑郁样行为及脑组织低氧、脑血容量降低。
  • NAFLD小鼠存在小胶质细胞和星形胶质细胞形态与代谢改变(耗氧量增高)。
  • Mct1单倍体不足小鼠虽脂肪堆积,但免于NAFLD及相关脑改变。

核心结论

  • 本研究为肥胖和NAFLD中脑健康受损提供了证据,强调肝-脑轴的重要性。
  • Mct1单倍体不足的保护作用提示该蛋白是预防和/或治疗NAFLD及相关脑功能障碍的新治疗靶点。
  • 作者认为NAFLD是严重健康风险,其对大脑的不良影响可能成为全球卫生系统和经济负担。
  • 作者呼吁医生系统筛查早期心理症状体征,并提醒高危个体关注这些潜在神经效应。

研究设计与样本

  • 研究采用饮食诱导NAFLD模型及Mct1单倍体不足(Mct1+/-)小鼠。
  • 小鼠接受对照饮食(普通饲料)或高脂饮食加水中高果糖/葡萄糖,持续16周。
  • 行为学测试后,在麻醉下用多光谱光声断层成像和光学荧光监测组织氧合、脑血管反应性和脑血容量。
  • 用离体高分辨率呼吸测定法测量皮层线粒体氧耗和呼吸能力,免疫荧光和3D重建评估小胶质细胞和星形胶质细胞改变。
  • 用EchoMRI评估体成分,组织学确认肝脂肪变性。

主要发现

  • NAFLD伴肥胖与焦虑和抑郁相关行为相关。
  • 观察到低度脑组织缺氧,可能归因于低度脑炎症和脑血容量降低。
  • 伴随小胶质细胞和星形胶质细胞形态和代谢改变(耗氧量更高),提示肥胖相关饮食诱导脑病的早期阶段。
  • Mct1单倍体不足小鼠尽管脂肪组织有脂肪积累,但免于NAFLD及相关脑改变。

临床怎么用

  • 作者呼吁医生系统筛查早期心理症状体征。
  • 作者提醒高危个体关注这些潜在神经效应。
  • 作者认为需要早期诊断和治疗NAFLD。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Non-alcoholic fatty liver disease (NAFLD) has been associated with mild cerebral dysfunction and cognitive decline, although the exact pathophysiological mechanism remains ambiguous. Using a diet-induced model of NAFLD and monocarboxylate transporter-1 (Mct1+/-) haploinsufficient mice, which resist high-fat diet-induced hepatic steatosis, we investigated the hypothesis that NAFLD leads to an encephalopathy by altering cognition, behaviour, and cerebral physiology. We also proposed that global MCT1 downregulation offers cerebral protection. METHODS: Behavioural tests were performed in mice following 16 weeks of control diet (normal chow) or high-fat diet with high fructose/glucose in water. Tissue oxygenation, cerebrovascular reactivity, and cerebral blood volume were monitored under anaesthesia by multispectral optoacoustic tomography and optical fluorescence. Cortical mitochondrial oxygen consumption and respiratory capacities were measured using ex vivo high-resolution respirometry. Microglial and astrocytic changes were evaluated by immunofluorescence and 3D reconstructions. Body composition was assessed using EchoMRI, and liver steatosis was confirmed by histology. RESULTS: NAFLD concomitant with obesity is associated with anxiety- and depression-related behaviour. Low-grade brain tissue hypoxia was observed, likely attributed to the low-grade brain inflammation and decreased cerebral blood volume. It is also accompanied by microglial and astrocytic morphological and metabolic alterations (higher oxygen consumption), suggesting the early stages of an obesogenic diet-induced encephalopathy. Mct1 haploinsufficient mice, despite fat accumulation in adipose tissue, were protected from NAFLD and associated cerebral alterations. CONCLUSIONS: This study provides evidence of compromised brain health in obesity and NAFLD, emphasising the importance of the liver-brain axis. The protective effect of Mct1 haploinsufficiency points to this protein as a novel therapeutic target for preventing and/or treating NAFLD and the associated brain dysfunction. IMPACT AND IMPLICATIONS: This study is focused on unravelling the pathophysiological mechanism by which cerebral dysfunction and cognitive decline occurs during NAFLD and exploring the potential of monocarboxylate transporter-1 (MCT1) as a novel preventive or therapeutic target. Our findings point to NAFLD as a serious health risk and its adverse impact on the brain as a potential global health system and economic burden. These results highlight the utility of Mct1 transgenic mice as a model for NAFLD and associated brain dysfunction and call for systematic screening by physicians for early signs of psychological symptoms, and an awareness by individuals at risk of these potential neurological effects. This study is expected to bring attention to the need for early diagnosis and treatment of NAFLD, while having a direct impact on policies worldwide regarding the health risk associated with NAFLD, and its prevention and treatment.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Hadjihambi A, Konstantinou C, Klohs J, et al. Partial MCT1 invalidation protects against diet-induced non-alcoholic fatty liver disease and the associated brain dysfunction. J Hepatol. 2022. PMID: 35995127. doi:10.1016/j.jhep.2022.08.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。